PR Newswire
08 May 2023, 20:30 GMT+10
![]() |
SAN FRANCISCO, HOUSTON and SINGAPORE, May 8, 2023 /PRNewswire/ -- Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced an upcoming poster presentation at IMMUNOLOGY2023.
The company will present preclinical data for HMBD-011, an anti-VH4-34 antibody developed with Hummingbird Bioscience's Rational Antibody Discovery platform. In preclinical models, HMBD-011 effectively inhibits cold agglutination and clears VH4-34+ antibodies in circulation within 24 hours. HMBD-011 also mediates clearance of VH4-34+ cells via antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis.
"HMBD-011 targets the small conserved conformational hydrophobic patch of VH4-34, which is challenging to target with traditional antibody discovery approaches. With its differentiated mechanism of action, HMBD-011 has the potential to address underlying disease pathology in lupus (systematic lupus erythematosus and cutaneous lupus erythematosus) and cold agglutinin disease," said Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer, Hummingbird Bioscience. "We look forward to sharing the preclinical data for our novel anti-VH4-34 antibody and discussing therapeutic strategies with the immunology community."
IMMUNOLOGY2023
Poster Session Title: Innovations in the Manipulation of T Cells for Treating Autoimmune Diseases
Poster Session Date: Sunday May 14, 2023
Time: 14:30 - 15:45 EDT
Poster Board Number: P768
About Hummingbird Bioscience
Hummingbird Bioscience is a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases. The Hummingbird Bioscience model combines computational and systems biology with wet lab drug discovery in a multi-disciplinary, collaborative environment spanning initial discovery through clinical development. We harness this integrated approach across target identification and patient selection, enabling our team to increase the efficiency of translating novel scientific insights while reducing the inherent risk in drug discovery and development. We are currently developing two clinical-stage assets: HMBD-001, a humanized anti-HER3 monoclonal antibody targeting a novel epitope on HER3, and HMBD-002, a humanized anti-VISTA IgG4 monoclonal antibody. Both programs are currently in Phase 1 studies. At Hummingbird Bioscience, our commitment to rigorous science, teamwork and intellectual integrity underpins our passion to accelerate the journey of new drugs from concept to clinic.
For more information, please visit www.hummingbirdbioscience.com, and follow Hummingbird Bioscience on LinkedIn, Twitter, and YouTube.
About HMBD-011
Developed with Hummingbird Bioscience's proprietary Rational Antibody Discovery (RAD) platform, HMBD-011 is an anti-VH4-34 antibody designed to target the small conformational hydrophobic patch of VH4-34. HMBD-011 selectively binds, blocks and depletes VH4-34+ autoantibodies and autoreactive VH4-34+ B cells, and has demonstrated efficacy in preclinical models. The differentiated mechanism of action of HMBD-011 has the potential to selectively target disease pathogenesis in systemic lupus erythematosus (SLE), cutaneous lupus erythematosus (CLE), and cold agglutinin disease (CAD), versus a broad B cell depletion and inhibition approach that risks compromising normal immune functions.
Get a daily dose of Vietnam Tribune news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Vietnam Tribune.
More InformationDHAKA, Bangladesh - Human Rights Watch has sharply criticized a plan to repatriate Rohingya refugees from Bangladesh to Myanmar, claiming ...
Diamir, Pakistan - According to the country's disaster management agency, at least 11 people were killed when an avalanche hit ...
KATHMANDU, Nepal - According to sources, Luis Stitzinger, the expedition leader of the German operator Amical Alpin, has remained out ...
KARACHI, Pakistan - Dr. Seemin Jamali, former executive director of the Jinnah Postgraduate Medical Centre (JPMC), died on Saturday night ...
RAKHINE STATE, Myanmar - According to Myanmar's ruling military, Cyclone Mocha killed at least 145 people this week.The impoverished western ...
KATHMANDU, Nepal - Nepal Airlines, the country's state-owned carrier, is one step closer to starting flights to Australia. Nepal Airlines' ...
WASHINGTON D.C.: The White House announced this week that President Joe Biden has chosen US Air Force chief General Charles ...
GUAM: After Typhoon Mawar brought strong winds and torrential rains, large areas of the US Western Pacific territory of Guam ...
NEW YORK CITY, New York: In one of the largest known Chinese cyber-espionage campaigns against American critical infrastructure, a state-sponsored ...
SAN FRANCISCO, California: Sam Altman, CEO of ChatGPT-maker OpenAI, has said the company could consider leaving Europe if it could ...
WASHINGTON D.C.: Reuters has reported that US President Joe Biden's nominee for a federal judge position in Kansas, Jabari Wamble, ...
WASHINGTON D.C.: Jennifer Homendy, head of the US National Transportation Safety Board, has said the US will investigate recent near ...